Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott M Rawls

Showing results (101-110 of 133) with videos related to

Pageof 14
Sort By:
Neurochemistry International|June 10, 2014
Cocaine-induced neuroadaptations in the dorsal striatum: glutamate dynamics and behavioral sensitizationVinay Parikh, Sean X Naughton, Xiangdang Shi, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 20, 2007
2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin AYulin Wang, Yong Chen, Wei Xu, et al.
Drug and Alcohol Dependence|December 6, 2021
Paradoxical anxiolytic effect of the 'bath salt' synthetic cathinone MDPV during early abstinence is inhibited by a chemokine CXCR4 or CCR5 receptor antagonistSteven J Simmons, Chicora F Oliver, Nicholas S McCloskey, et al.
Psychopharmacology|October 20, 2018
Synthetic cathinone adulteration of illegal drugsChicora F Oliver, Joseph J Palamar, Alberto Salomone, et al.
Physiology & Behavior|July 25, 2024
Clavulanic acid inhibits methamphetamine locomotor sensitization in mice and normalizes methamphetamine-induced changes in glutaminase mRNA levels in the nucleus accumbensTaylor Hawthorne Walters, Sonita Wiah, Aryan Shekarabi, et al.
Neuropharmacology|April 18, 2016
Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activatorRyan A Gregg, Callum Hicks, Sunil U Nayak, et al.
Life Sciences|July 1, 2023
Cannabinoid mechanisms contribute to the therapeutic efficacy of the kratom alkaloid mitragynine against neuropathic, but not inflammatory painDaniel J Farkas, Saadet Inan, Laila N Heydari, et al.
Neuroscience Research|February 2, 2025
Positive allosteric modulator of GLT-1 reduces methamphetamine hyperlocomotion, sensitization and conditioned place preference in micePrateek Mokkarala, Sonita Wiah, Ellen M Unterwald, et al.
Drug and Alcohol Dependence|December 15, 2022
Troriluzole inhibits methamphetamine place preference in rats and normalizes methamphetamine-evoked glutamate carboxypeptidase II (GCPII) protein levels in the mesolimbic pathwaySonita Wiah, Abigail Roper, Pingwei Zhao, et al.
Brain, Behavior, and Immunity|September 29, 2022
Purinergic P2X7 receptor antagonist inhibits methamphetamine-induced reward, hyperlocomotion, and cortical IL-7A levels in mice: A role for P2X7/IL-17A crosstalk in methamphetamine behaviors?Raghava Potula, Taylor A Gentile, Joseph J Meissler, et al.
Pageof 14

Showing results (101-110 of 133) with videos related to

Sort By:
Pageof 14
Neurochemistry International|June 10, 2014
Cocaine-induced neuroadaptations in the dorsal striatum: glutamate dynamics and behavioral sensitizationVinay Parikh, Sean X Naughton, Xiangdang Shi, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 20, 2007
2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin AYulin Wang, Yong Chen, Wei Xu, et al.
Drug and Alcohol Dependence|December 6, 2021
Paradoxical anxiolytic effect of the 'bath salt' synthetic cathinone MDPV during early abstinence is inhibited by a chemokine CXCR4 or CCR5 receptor antagonistSteven J Simmons, Chicora F Oliver, Nicholas S McCloskey, et al.
Psychopharmacology|October 20, 2018
Synthetic cathinone adulteration of illegal drugsChicora F Oliver, Joseph J Palamar, Alberto Salomone, et al.
Physiology & Behavior|July 25, 2024
Clavulanic acid inhibits methamphetamine locomotor sensitization in mice and normalizes methamphetamine-induced changes in glutaminase mRNA levels in the nucleus accumbensTaylor Hawthorne Walters, Sonita Wiah, Aryan Shekarabi, et al.
Neuropharmacology|April 18, 2016
Synthetic cathinone MDPV downregulates glutamate transporter subtype I (GLT-1) and produces rewarding and locomotor-activating effects that are reduced by a GLT-1 activatorRyan A Gregg, Callum Hicks, Sunil U Nayak, et al.
Life Sciences|July 1, 2023
Cannabinoid mechanisms contribute to the therapeutic efficacy of the kratom alkaloid mitragynine against neuropathic, but not inflammatory painDaniel J Farkas, Saadet Inan, Laila N Heydari, et al.
Neuroscience Research|February 2, 2025
Positive allosteric modulator of GLT-1 reduces methamphetamine hyperlocomotion, sensitization and conditioned place preference in micePrateek Mokkarala, Sonita Wiah, Ellen M Unterwald, et al.
Drug and Alcohol Dependence|December 15, 2022
Troriluzole inhibits methamphetamine place preference in rats and normalizes methamphetamine-evoked glutamate carboxypeptidase II (GCPII) protein levels in the mesolimbic pathwaySonita Wiah, Abigail Roper, Pingwei Zhao, et al.
Brain, Behavior, and Immunity|September 29, 2022
Purinergic P2X7 receptor antagonist inhibits methamphetamine-induced reward, hyperlocomotion, and cortical IL-7A levels in mice: A role for P2X7/IL-17A crosstalk in methamphetamine behaviors?Raghava Potula, Taylor A Gentile, Joseph J Meissler, et al.
Pageof 14